Good day, thank you for standing by. Welcome to the Nanophase second quarter 2023 financial conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. The words believes, expects, anticipates, plans, forecasts, and similar expressions are intended to identify forward-looking statements. Statements contained in this news release that are not historical facts are forward-looking statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements reflect the company's current beliefs and a number of important factors that could cause actual results for future periods to differ materially from those expressed in this news release. These important factors include, without limitation, a decision of the customer to cancel a purchase order or supply agreement, demand for and acceptance of the company's personal care ingredients, advanced materials, and formulated products, changes in development and distribution relationships, the impact of competitive products and technologies, possible disruption in commercial activities occasioned by public health issues, terrorist activity, and armed conflict, and other risks indicated in the company's filings with the Securities and Exchange Commission. Nanophase undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. I would now like to hand the conference over to your speaker today, Jess Jankowski, President and CEO. Please go ahead. Thank you, Abigail. Good morning to all of those listening live. We also welcome those who choose to listen later online. Thanks for joining us today for our discussion of our second quarter 2023 results, the state of the business, and our outlook for the rest of the year. Kevin Cureton, our Chief Operating Officer, is joining me on the call today. Our prepared comments will be brief, and as always, we're looking forward to some good Q&A afterward. Our second quarter was much stronger than the first, still beneath our expectations when entering 2023. While there's definitely room for improvement, there's also definitely room for optimism as we assess our performance. On the last call, I mentioned that margin improvement and profitability are a major focus for the company. We discussed the plans we've put into place, and I told you we expected to see at least a 2% improvement to gross margin this year. With that commitment in mind, it was gratifying to see the 31% gross profit in Q2 and also to see the improvement compared to the prior year's Q2 and the six-month numbers. These numbers are even better when taking into account that we had more than $400,000 in other revenue in Q2 of 2022, which added about 4% to the quarterly margin last year and 2% to the six-month margins. If we pull this other revenue out, which practically represented all profit, year-over-year, we saw a 4% improvement in gross profit for the first half, even after a historically tough Q1, and an 11% improvement over the second quarter. We continue to struggle with unsteady customer demand, which, while continuing to grow, pops up and down month-to-month. This makes it challenging to predict future margins over short windows like a three-month quarter. We've also historically struggled with getting product out the door due to external supply chain issues and internal bottlenecks. The good news here is that most of our external supply chain issues have been resolved. We've also seen some nice productivity improvements coming online recently, which will help to reduce internal bottlenecks. Kevin will touch on this during his comments as well. Moving down to P&L, it's also important to recognize that we're incurring expenses relative to the litigation with BASF that we believe will not reflect ongoing operating expenses once we resolve the open issues. We spent roughly $1 billion here during the six months ending June 30th, distributed almost equally in the two quarters. That comes to a bit more than $0.02 per share, and were these costs not incurred, we'd be looking at a profitable six months and about a 7% net income for Q2. We did incur these costs, however, and we will continue down the path we're on, ideally to a negotiated settlement, but not necessarily so. We think we have a good case and continue to work to resolve these issues with BASF as quickly and fairly as is practical. We're approaching this situation in light of our view that Nanophase and Solesence promise a great deal of unrecognized value that we intend to realize. We need to protect that value and ideally help to expand both our active pharmaceutical ingredient, or API, business with BASF by adding new products, which remains an ongoing discussion. We will also enhance that value by driving more growth through the expansion of our Solesence business. Before we continue, let's walk through the numbers. Unless identified otherwise, all numbers will be stated in approximate terms. Our Q2 2023 revenue was $11.9 million versus $11.2 million for the same period last year, up 6%. At $11.9 million, Q2 of 2023 also represents the highest quarterly revenue we've ever recorded. A few short years ago, $12 million would have represented a pretty good year for your company. As an additional point of reference, Q2 2023 revenue exceeded Q1 revenue by 25%. For the second quarter of 2023, we had a net income of $337,000, or $0.01 a share, which represented a multiple of 2022 second quarter earnings of $50,000, coming in at well less than $0.01 a share. Looking at the six-month comparable numbers, we had $21.3 million in revenue in the first half of 2023, versus $19.4 million in the same period in 2022. This represented a 10% improvement year-over-year. Also, when looking at the strides made since 2022, note that we had a good deal of other revenue that, that came from sources not directly related to product revenue, which is our core business. Looking only in terms of product revenue growth, the 6% improvement in Q2 goes up to 10%. Taken the same way, the increase for the six-month period goes from 10%- 12%. These are good indicators of where our business is headed and how we plan to strengthen it going forward. Our ongoing challenges are to balance production resources to demand and to continue to increase throughput to help reduce our reliance on overtime and to avoid having unabsorbed direct labor during periods of waning demand. We've been having success in addressing these things. As we mentioned in the release, we recently commissioned our first fully automated filling process, enhancing throughput per labor hour by 100%. We continue to work to automate more of our processes where demand can support it, with expectations that this will bring benefits not only in enhancing our ability to deliver, but also to reduce costs. Keep in mind that even without the additional automation, we're still producing at record levels. As we get our new manufacturing organization humming, we'll continue to deliver on opportunities to produce more efficiently and profitably. We're in a good spot. As I mentioned last time, we're highly focused on increasing our margins, knowing that this will yield significant increases, first in profitability, then to our enterprise valuation. We're all investors in Nanophase and Solesence, and we all stand to reap the rewards we're working toward together. Looking now at operating expenses, we saw R&D expense, which includes our engineering group, while down a little from Q1, was up 35% year-over-year. Roughly half of that increase was related to compensation expense. An important part of this came from the expansion of our engineering team to help speed the build-out of capacity in our new Bolingbrook facility. These types of additions will pay for themselves. The rest of the R&D investment in people is to support the continued enhancement of our technology, our intellectual property, and ultimately, our highly rated line of award-winning innovative products. We operate in markets, particularly with respect to our Solesence business, where new products drive growth and product cycles can be fairly short. We've made remarkable progress since we started developing and marketing our formulated products, and we're working to maintain the advantage we have. Moving to SG&A expenses, which were also down sequentially from Q1, we were up just over $1 million year-over-year to about $4.3 million for the six months of 2023. Of this increase, the lion's share related to the $1 million in BASF litigation costs we incurred this year. Again, we don't expect these to be ongoing expenses. Also contributing to this variance were smaller increases in compensation expense, insurance costs, and audit fees, offset by reductions in bad debt expense and other items. We also saw interest expense more than triple, a $280,000 increase from the same period in 2022, due to the combination of expanded borrowing and a 5% increase in the prime lending rate over the past year or so. As you can see, we keep moving ourselves into a better position to win. We've maintained our focus on capturing the bottom line benefits that the changes we've implemented beginning in 2022 were designed to deliver. The bottom line takeaway here is that we're focused, motivated, and working hard to build the value of our company. Now, I'd like to introduce Kevin Cureton, Chief Operating Officer, to discuss progress in some of these areas and their drivers in greater detail. Kevin? Thanks, Jess. As always, I would like to begin by thanking our team for their efforts in helping fulfill our mission in enhancing people's lives through the world's best skincare products, as we also work tirelessly toward creating a more valuable company for our shareholders. I also would like to thank all of our investors who remain steadfast in their support of our company. While it was nice to return to profitability in Q2, it by no means represents a finish line of any sort. Instead, Q2 represents us starting to realize our goal on achieving both growth in revenue and increased profitability. A critical part in achieving our goal is having the right team in place. We now, for the first time since we began the Solesence business, have a complete leadership team in place in commercial, operational, and financial roles that will serve as the team to lead us into the future. We have already demonstrated that our business processes enable us to sustain our status as a world-class innovator. Our latest CosmoProf Award really reinforces that. That is why we are increasingly focused on building the business processes that will enable us to become a best-in-class manufacturer and distributor. As our board often asks, "How will this translate? What are the KPIs that will demonstrate that we are on track with achieving our goal?" Achieving operational excellence translates into meaningful improvements in gross profit margins. Over the next two quarters, that will primarily be through improvements in two key areas, our labor efficiency and lowering materials costs. While 31% gross profit was certainly a significant improvement over the underperformance we had in the previous quarters, we believe there is much more improvement that can be realized in a relatively short period of time. I'll end my comments by saying that our confidence in the future, again, is largely because of our confidence in our team's ability to achieve our mission. Continued innovative leadership while simultaneously growing our profitability. They have the right stuff to achieve our vision, but of course, that must be proven during the rest of this year and the years to come. Jess? Thanks, Kevin. Why don't we dig right in? Although we know that most of our investors listen to the webcast to review the transcript after the live call, we'd like to invite those participating in today's call to ask any questions you may have or to share your comments. Afterward, I'll offer a few critical closing comments. Abigail, would you please begin the Q&A session? Thank you. At this time, we'll conduct the question and answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. One moment while we compile the Q&A roster. Our first question comes from the line of Tony Rubin, an individual investor. Your line is open. Hi, good morning, gentlemen. I'm very pleased with this quarter. I can see from your tone that you guys are much happier having the call this quarter than the previous quarter. A little bit. Kevin, I really liked your comment about much more improvement that can be realized in a short period of time. Given that you've made, you know, great strides in gross margin improvement, though not where you were two years ago, what do you think is a, you know, end-of-year gross margin target or a steady state gross margin target? Anything you can share on that? Well, it's, it's hard to say because, I mean, as, as big as we feel we are, we're a really small company. One of the things that was great about Q2 is we had production that aligned very well. It was easier to schedule than it's been historically, not, not lumpy as much. That's where, you know, Q1 was financially, looked like a disaster, but as, as we talked back then, if you looked at January, then February, then March, March was a good month. It's just that we had such a dip in January that made it difficult. When it comes to what the year is going to be, I think we need more steady state operation to lock that down regularly, because Q4, generally, just in this business, you have, you have two things. The API business usually peaks somewhere between Q1 and Q2, and a little bit in the beginning of Q3. Then the Solesence business, the Q4 volume that comes through there generally is going to be setting up for launches in Q1, versus the volume that comes on for reorders and everything else when you're getting into later Q1, Q2, Q3. That's where I, I generally expect Q4 to, to dip down. you know, do we, do we hit 31% or more through the rest of the year for both quarters? I don't know. I, I think probably not when we get into Q4, but certainly it's possible. Q3 will depend on order volume and how variable it is. So far, it's been good, and July was actually an okay month, given that you have the holidays in there, Mm-hmm. And do our annual maintenance and things like that, usually around that week. I think we get expected to continue to move up. It's going to be better than last year, I said by a few points when we talked last, partly because we just had such a tough Q1 to make up from. I think steady state at some point for this company can easily be over 30% and probably getting up toward the 40% range. That's something that we're very into doing, working on, and it's also something that our board of directors is very demanding when it comes to. You know, that's, that's in the works. Okay, now, that's, I, I understand that. To be honest, I hadn't ever really, completely understood your, your seasonality. Discussing your revenue growth, in your, your, press release, you mentioned a $15 million backlog going into Q3, which I take from your comments, not to mean that that will all be recognized in Q3. Do you, do you typically then, you know, take your backlog one quarter out, two quarters out, three quarters out? Well, what we said there, and it's partly, you, you hate to make this into a word salad, which obviously for you, we did. You know, leaving June 30th, so when, when we put the press release together, between what we've already shipped and what's on the books, we've got $15 million in volume, of which two-thirds of that $15 million reflects potential Q3 volume. You know, that's you're in the $10 million plus range, depending on what else we can pull in. We are expecting more orders coming in for Q4, which is the balance of most of those orders, and then we have a few orders so far in for 2024. We expect more as we go. We try to use that, that metric. I think when, when we get a more steady state flow of business, it will be easier for us to say, "We have X amount planned for Q4, plus or minus, you know, or Q3, plus or minus whatever, 10%, and then we have X amount for Q4," but we're not quite there yet. Hey, Tony, just to add one more comment to what Jess offered. It's a little different in 2023 than it has been in, in previous years because there was a lot, as I'm sure you know, as, as well or better than us, there was a lot of concern in consumer markets about what was gonna happen to the economy. There was a lot of inventory control that was happening on the retail end that then fed back to our clients, which then ultimately fed to us in terms of just timing on orders. You know, they were holding back and still are, you know, anticipating or giving us indication that there's demand out there and that they're gonna place orders, but they're waiting to the very last moment these days, versus being a little bit more aggressive as they were in 2021 and 2022 and placing orders further ahead. That, that's part of the reason why we're not giving as much guidance on the total volume, because we don't have as much visibility as we might have had in last year, just based upon the behavior of the client base. I, I, I will finish by saying that doesn't mean that there's a weakness in the business per se. It's just a change based upon the whole channel being more conservative on inventory. Okay. No, that's an excellent point, right? I mean, people were just scrambling to lock in. Just one final question, and I'll obviously give others a, a chance. I'm used to kind of being at the end, not the beginning. Jess, in your comment about BASF, and not to use your words, word salad it, but, are you implying that BASF's claim or their litigation revolves, at least in part, around looking for more product support going forward and perhaps feeling neglected because the company has emphasized Solesence, as opposed to something else or different? Obviously, you haven't reached a settlement, so there's, there's nothing definitive. That, that was something I, I thought I heard you suggest in your comment. Well, I, I'm pretty limited on what we can share there. One thing is that we've... The commercial relationship and the, the litigation have been, for the most part, in this past year now, that this is almost going on, have been segregated pretty well. We are consistently in discussions about new products and getting new products out there. I think they, you know, they're, they're smart people, they're good at what they do, and I think they're recognizing, as we recognize, which is obvious in our other business, that you just have to have more products out there. We are, we're continuing to talk about that. With respect to what motivated them relative to their claims, I think the I think they said it in their, in their claims that I don't want to recount them because I won't do it accurately enough, and I can hear my attorney holding, not reading right now, holding his breath. I, I think that the we had some stumbling on delivery, which was difficult when everything went, you know, the supply chain issues were what they were, and that was problematic for them. We have, they certainly are interested in new products, but that really isn't anything that is baked into our existing contract or part of the litigation. With respect to to Solesence, you know, the, the, the two businesses are very separate from one another. Although, from the outside looking in, obviously, we had more to do, but we continued to service that business as best we could, and we don't think that there was any kind of a diminution of, of quality relative to our API business as we built the Solesence volume. All right. Well, well, thank you, gentlemen, and I'm glad to see that you guys have turned the corner, and congratulations. Thank you. Thanks, Tony. One moment for our next question. Our next question comes from Ron Richards, a private investor. Your line is open. Hi, Jess. Hey, Ron. You might already have answered my question. I had a little trouble logging in today, through no fault of yours. My phone was on Not Disturb, but that being the case, I missed out on your comments about the lawsuit. When, when is the next court proceeding, and what, what would that court proceeding be? Or, when, when is the next court date, and what would be argued on at that date? Well, the next, in my view, the most significant date coming up is the end of the year. We have discovery extended till 12/31, so we've got a fairly good deal of runway to work toward a negotiated settlement, if that's what ends up happening. There are- Now, is that, Oh, excuse me. Is. There are... Go ahead. I'm sorry. Was the discovery extended because of the amount required or because of the possibility for settlement? It was because we were, and we have been, working together and, and trying to resolve these issues, out of court, if possible, which everybody prefers, including the court. We extended that to, to allow time to do that while still retaining any, any time we needed, you know, should we end up, having to litigate this thing all the way. Have any of the issues been narrowed down in any sort of motion procedure or settlement, or is it just sort of the original claim as it first stood? I wouldn't say that any of them have been, there's been no motions or procedures that have changed any of the original issues. I would say that we are working together, have identified the things that we need to address, the open issues, and we've been doing that on a fairly regular basis. I'm optimistic we can work something out that's good for both companies, which any settlement has to be. I can't say really anything more than that. Okay. Well, it does look like you've transitioned through your expansion, and I'm glad to see that. I sure hope this lawsuit can be settled in a way that keeps Solesence on the roll. R-O-L-L. Yeah. We think we're in good shape there. Again, can't speak for what happens when you litigate, which is partly one of the reasons it's good, if you can, to come up with an amicable settlement. Well, thank you. Okay. Talk to you around. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. Our next question comes from James Lieberman with Revere Securities. Your line is open. Great. Thank you very much. My, my handset broke. Can you hear me okay? Yep. Hi, Jim. Oh, great. Hi there. Great, great quarter. Very impressive, considering also some of the dropping off, I'm guessing, of some of the COVID testing technology. Could you give a little bit more clarity, and maybe you've already maybe you have, and I didn't quite fully understand it, of how the integration into the new facility is going? I imagine it's still a process. Can you give a little bit more sense of where that how that process is playing out? Thanks, Jim. I appreciate it. We'll, we'll talk about it in stages because it will happen in stages. Our expectation from the beginning is that it was a multi-year process, in large part, to make sure that we didn't have any disruption in supply to our key clients or all of our clients, really. What we have completed so far is the move of our warehousing and all of our filling and assembly or the back end of the Solesence manufacturing processes. We had completed the move of those, well, the warehousing as early as last year, this time. Then the filling operations was completed in the end of January, beginning of February of this year. Over the last few months, we spent most of the time really consolidating, some of the new equipment that had been installed and really, quite honestly, the changes to operating procedures that resulted from our expanded footprint and capability. That was really what we spent most of the last few months dealing with, including now having a new manufacturing leader on, on the team, who started at the beginning of June. Still a work in progress through the rest of the expansion, which we hope to happen over the next, or consolidation, depending upon your way of put- of viewing it, over the next couple of years, through putting the rest of our upstream operations into the same facility as our current packaging and warehousing. Oh, that's terrific. I really like the methodical way in which you're going about this. These are terrific accomplishments. You know, a lot of companies don't manage those transitions very well, and the fact that you've got these parallel systems still in place while you're managing it, is very, is very commendable. Could you also comment on some of the brand names again, that we might, or that we might see Solesence? Is it Kleair is one, and there's another one beginning with a B, that you- Yeah, there- identifiers? Yeah. Yeah. Those are, those are Solesence related brand names, Jim. Kleair, K-L-E-A-I-R, which everybody always laughs about. Anyway, that is the name of our how we brand our zinc oxide. What you really-- I think you may be alluding to is last, last call, we talked about some of our clients that, that allow us to reference them publicly. We have companies like Colorescience, who we've often talked to as being our launch partner. They were really our first client in the in the Solesence business. We have other companies like KINLO, which is the Naomi Osaka brand. We have Credo Brands, which are products that Credo, the retailer, manages. We have a company called Relevant, who lets us talk about them, and Bloomeffects, who also lets us talk about them. These are all companies that are primarily distributed in, in places like Sephora or Ulta or other specialty beauty retailers. There are, you know, dozens of others that we're not able to reference publicly yet, but are clients of ours. Well, that's very helpful. That's probably the most complete list I've, I've heard to date. Thank you very much. This is just a random question, but, how many SKUs do you think you're, you're on right now? Yeah, we had a fun discussion about that. I, I guess it depends, actually, talking to one of our supplier partners. By the way, it's defined by the FDA, we have almost 500 SKUs. And just to be clear, we could have a-- the same bulk in three different packages, and that would be by the FDA's perspective, three SKUs. So yeah, we're, we're closing in on about 500 SKUs that we have active currently. All right. I just want to wrap up by saying, what a, what a terrific job, well done with all these challenges. Thank you very much again. Congratulations. Thanks, Jim. Yeah. Thank you. As a reminder, to ask a question, please press star one, one on your telephone. Our next question comes from the line of Stefano Bullis, an individual investor. Hello, hi, everyone. Stefan, your line is open. Hello, hi, everyone. First of all, well done for the results in the quarter and the Cosmoprof award. I've seen, I think it was on LinkedIn, a post related to Cosmoprof in Italy in 2024. Is it the first time you participate to that one in Italy? Yeah, we have not yet participated in the Italian event, which I'm sure you may know, is the largest event. Wasn't really appropriate for us up until now, in large part because of our footprint and our presence. Given the what's gonna happen because we were a winner again of the best formulation, our company is actually being highlighted, or one of the companies being highlighted at that event. It's an ideal time to, you know, broaden our introduction, if you will, to Europe. That's part of our plan. So that would also suggest you, you now feel you have a more robust infrastructure to cope with the increased volumes in case you are opening new, new markets? That's correct. We with the really expansion, we mentioned it in the press release, some of the new automation that we've already installed, there's still some more that is on its way, literally as we speak, for installation. We have really, for the first time, addressed our downstream capacity issues as a company. We're really in a good position from that standpoint. There's still some opportunity for us to improve upstream of, of that, as it stands today, we're certainly able to meet the demand that we have and look for additional demand out there. Okay. One more. With regards to this equipment for completing the enhancement of end-to-end automation that you were expecting this quarter, is this... Everything is on track compared to the timeline indicated in the previous call? Yes. Actually, we are still on schedule with what we had anticipated. We completed the validation on, you know, the, the biggest of the lines. We have, the, yeah, the secondary packaging lines are still on the same schedule we had anticipated. As a result, we anticipate the, the same improvements that we had talked about previously. Okay. Thanks a lot. I'm happy that this quarter I managed to order some of your products, because I'm not based in U.S., and it was always difficult to find customers of yours that are selling outside of the U.S. But with Soles-- Colorescience, I found a way to- Yes. Buy some products finally. Yeah. Yeah, I would say, you know, increasingly, I, I would expect a big hint that there will be some more announcements related to that in Q1 of 2024. We do have some new clients that one of which is you're actually based in Europe, that it'd be launching, and they'll happily talk about their relationship with Solesence. As after that launch, we'll certainly be excited to have you buy those products as well. Okay. Thanks a lot. Thank you. Thank you. Buon sera. I'm showing no further questions at this time. I would like to turn it back to Jess Jankowski for closing remarks. Thank you, Abigail. As I mentioned, there are a few closing remarks that I want all of you to hear. Our story of the last few years has been one of unrealized value. We've become bigger and more stable. Now we have to become more profitable, then ultimately, more valuable. Demand for our products has not diminished. We're working hard to get them out of the door faster and to introduce more of them. Consumer preference continues to move Solesence forward, and it has had the effect of insulating us from the ups and downs in our economy. We're growing and winning customers and winning new brand partners and consumers. Your patience is going to pay off as we transition to this next phase of development. Thank you again for joining us today. We'll look forward to our next call, when we expect to discuss further improvements to the profitability and stability of our business. Have a great day, everybody. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.